Prolactin-secreting tumors and hypogonadism in 22 men.
We studied 22 men with prolactin-secreting pituitary tumors and hypogonadism. Twenty complained of impotence, nine had visual impairment, and three experienced galactorrhea. None of the 17 patients undergoing operation or radiotherapy, or both, were subsequently normoprolactinemic. In all 13 patients treated with bromocryptine major clinical improvement was associated with a decrease in serum prolactin levels and in nine with an increase in serum testosterone. Two patients receiving testosterone replacement therapy showed improved potency only after bromocryptine was administered. The results indicate that hyperprolactinemia frequently induces hypogonadism in men, that bromocryptine ameliorates symptoms of disease previously unchanged by operation or radiotherapy, and that the impotence observed may not be solely the result of hypogonadism.
D000239:Adenoma, Acidophil / Q000097:blood / Q000378:metabolism / Q000628:therapy; D000238:Adenoma, Chromophobe / Q000097:blood / Q000378:metabolism / Q000628:therapy; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000209:etiology; D005260:Female; D005687:Galactorrhea / Q000209:etiology; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000209:etiology*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000378:metabolism* / Q000628:therapy; D011247:Pregnancy; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use; D014786:Vision Disorders / Q000209:etiology
D001971:Bromocriptine; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone